1. Protein Tyrosine Kinase/RTK
    JAK/STAT Signaling
  2. EGFR
  3. Cetuximab

Cetuximab (Synonyms: C225)

Cat. No.: HY-P9905 Purity: 99.70%
Handling Instructions

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab has potent antitumor activity.

For research use only. We do not sell to patients.

Cetuximab Chemical Structure

Cetuximab Chemical Structure

CAS No. : 205923-56-4

Size Price Stock Quantity
1 mg USD 280 In-stock
Estimated Time of Arrival: December 31
5 mg USD 670 In-stock
Estimated Time of Arrival: December 31
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

Publications Citing Use of MCE Cetuximab

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab has potent antitumor activity[1].

IC50 & Target[1]

EGFR

0.147 nM (Kd, Fixed A431 cells)

Soluble EGFR

0.201 nM (Kd)

In Vitro

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a Kd of 0.147 nM for EGFR in fixed A431 cells by ELISA[1]. Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G0/G1 arrest, induces apoptosis, and reduces Rb, p27KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells[3].

In Vivo

Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts[2].

Clinical Trial
Molecular Weight

145543.35

CAS No.

205923-56-4

SMILES

[Cetuximab]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

Purity: 99.70%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

CetuximabC225C 225C-225EGFREpidermal growth factor receptorErbB-1HER1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product name:
Cetuximab
Cat. No.:
HY-P9905
Quantity:
MCE Japan Authorized Agent: